Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) was the target of some unusual options trading on Monday. Traders purchased 4,326 put options on the stock. This represents an increase of approximately 197% compared to the average volume of 1,456 put options.
Insider Activity at Corcept Therapeutics
In other news, insider Joseph Douglas Lyon sold 5,443 shares of the firm’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $26.00, for a total value of $141,518.00. Following the transaction, the insider now owns 7,314 shares of the company’s stock, valued at approximately $190,164. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $22.00, for a total value of $48,400.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Joseph Douglas Lyon sold 5,443 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $26.00, for a total value of $141,518.00. Following the transaction, the insider now owns 7,314 shares in the company, valued at approximately $190,164. The disclosure for this sale can be found here. Insiders have sold a total of 83,783 shares of company stock worth $2,118,996 over the last 90 days. Insiders own 18.60% of the company’s stock.
Institutional Trading of Corcept Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. FinTrust Capital Advisors LLC acquired a new stake in shares of Corcept Therapeutics in the third quarter valued at approximately $27,000. FNY Investment Advisers LLC acquired a new stake in Corcept Therapeutics during the 4th quarter valued at $32,000. Gladius Capital Management LP bought a new position in Corcept Therapeutics during the fourth quarter worth $36,000. GAMMA Investing LLC increased its holdings in shares of Corcept Therapeutics by 90.6% in the first quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 579 shares during the last quarter. Finally, Planned Solutions Inc. acquired a new position in shares of Corcept Therapeutics in the fourth quarter valued at $45,000. 93.61% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
View Our Latest Report on Corcept Therapeutics
Corcept Therapeutics Price Performance
Shares of NASDAQ:CORT opened at $22.30 on Tuesday. The company’s 50-day moving average price is $23.89 and its two-hundred day moving average price is $25.44. Corcept Therapeutics has a one year low of $20.84 and a one year high of $34.28. The stock has a market capitalization of $2.32 billion, a PE ratio of 23.47 and a beta of 0.48.
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last posted its quarterly earnings results on Thursday, February 15th. The biotechnology company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03. The firm had revenue of $135.41 million during the quarter, compared to the consensus estimate of $129.27 million. Corcept Therapeutics had a return on equity of 21.98% and a net margin of 21.86%. The business’s revenue was up 31.4% compared to the same quarter last year. During the same period last year, the company earned $0.14 earnings per share. On average, analysts anticipate that Corcept Therapeutics will post 0.92 earnings per share for the current fiscal year.
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Further Reading
- Five stocks we like better than Corcept Therapeutics
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- Election Stocks: How Elections Affect the Stock Market
- Merger or Not, Albertson’s Companies is a Good Buy
- How to Calculate Options Profits
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.